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Mindfulness-based cognitive therapy (MBCT) is an effective
group skills-training programme originally designed to prevent
depressive relapse/recurrence. Numerous studies have shown that
MBCT is also associated with a reduction in depressive
symptoms,1–8 which not only are harmful in the short term, but
also increase risk for subsequent relapse.9 It combines methods
of mindfulness training10 with features of cognitive therapy for
depression.11,12 In the initial studies on MBCT, Ma & Teasdale13
and Teasdale et al14 found that MBCT was associated with
differential risk of relapse, in that only patients with three or more
episodes of depression benefitted. Based on these findings,
patients with fewer than three episodes of depression are now
routinely excluded a priori in studies examining the effectiveness
of MBCT in depression.3,5,15–17 Even when studies focused on
residual depressive symptoms rather than relapse prevention,
samples typically were restricted to patients with three or more
depressive episodes.2,7,8,18 This restriction, however, is
questionable, especially since patients with residual symptoms
were actually excluded in the initial studies on differential relapse
prevention.13,14 Nevertheless, National Institute for Health and
Clinical Excellence guidelines19 recommend MBCT only as a
relapse/recurrence prevention programme for patients with three
or more prior episodes of major depression. The question arises,
therefore, to what degree patients with persistent and harmful
residual symptoms but only one or two prior depressive episodes
currently are deprived of a treatment that may alleviate chronic
complaints as well as influence the course of illness.20 The
aim of the current study was to examine the efficacy of MBCT
on reduction of residual depressive symptoms in a currently
non-depressed sample with residual depressive symptoms,
explicitly comparing individuals with a history of only one or
two prior episodes of major depression with individuals with three
or more episodes.
Method
Trial design
The current study (MindMaastricht; trial number NTR1084,
Netherlands Trial Register) was an open-label, parallel randomised
controlled trial (RCT). Participants were randomised to continue
with their usual treatment (if any; waiting list control condition)
or to receive 8 weeks of MBCT in addition to their usual treatment
(if any). Randomisation was stratified according to number of
depressive episodes (one or two v. three or more). An independent
researcher not involved in the project generated the randomisation
sequence in blocks of five (using the sequence generator on
www.random.org), and wrote the randomisation code in sealed
numbered envelopes. Power calculations showed that the present
study had 80% power for detecting a difference of medium effect
size (f 2 = 0.15, or d= 0.5)21 in differential effect of MBCT
depending on number of prior episodes of depression (one or
two v. three or more). Furthermore, our sample size of 130
participants is comparable with or greater than previous
samples (such as Barnhofer et al,2 Kingston et al,7 Ma &
Teasdale,13 Teasdale et al,14 Hargus et al18).
Participant characteristics
Adults with residual depressive symptoms after at least one episode
of major depressive disorder were recruited from out-patient mental
health care facilities in Maastricht and through posters in public
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Background
There appears to be consensus that patients with only one
or two prior depressive episodes do not benefit from
treatment with mindfulness-based cognitive therapy (MBCT).
Aims
To investigate whether the effect of MBCT on residual
depressive symptoms is contingent on the number of
previous depressive episodes (trial number NTR1084).
Method
Currently non-depressed adults with residual depressive
symptoms and a history of depression (42 prior episodes:
n=71; 53 episodes: n=59) were randomised to MBCT
(n=64) or a waiting list (control: n=66) in an open-label,
randomised controlled trial. The main outcome measured
was the reduction in residual depressive symptoms (Hamilton
Rating Scale for Depression, HRSD-17).
Results
Mindfulness-based cognitive therapy was superior to the
control condition across subgroups (b=70.56, P50.001).
The interaction between treatment and subgroup was not
significant (b=0.45, P=0.16).
Conclusions
Mindfulness-based cognitive therapy reduces residual
depressive symptoms irrespective of the number of previous
episodes of major depression.
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spaces offering mindfulness training to people with mild depressive
complaints in the context of a research project. Residual symptoms
were defined as a score of seven or higher on the 17-item Hamilton
Rating Scale for Depression (HRSD)22 at the time of screening.
Exclusion criteria were: fulfilling criteria for a current depressive
episode, schizophrenia, psychotic episodes in the previous year
and recent (previous 4 weeks) or upcoming changes in ongoing
psychological or pharmacological treatment. Currently depressed
individuals were excluded because MBCT was developed as a
relapse prevention programme and, at the time of trial preparation,
the view was that current depression might complicate participation
in MBCT.12,14 Relevant sociodemographic and clinical characteristics
are displayed in Table 1.
Sampling procedures
All study procedures were approved by the standing Medical
Ethics Committee of Maastricht University Medical Centre, and
all participants signed an informed consent form. An initial
telephone screening of potential participants was performed to
check for availability during the study period and likelihood of
meeting inclusion and exclusion criteria. A second in-person
screening included administration of the Structured Clinical
Interview for DSM-IV Axis I (SCID-I)23 and the 17-item HRSD
by trained psychologists. Eligible participants were invited for a
detailed one-to-one explanation of the study procedures, and then
took part in the baseline assessment (which included the HRSD and
the Inventory of Depressive Symptoms (IDS);24 see Geschwind et
al20 for more details). After completion of all baseline assessments,
the researcher allocated participants to their treatment condition
based on the randomisation code in the sealed envelope. Envelopes
were opened in order of sequence. No masking of treatment
condition took place (although the therapists were masked to the
number of prior major depressive episodes). After either 8 weeks
of MBCT (see Intervention) or equivalent waiting time (in the
control condition), post-assessments took place. All participants
received gift vouchers worth 50 euros (mainly to compensate for
the effort associated with another part of the pre- and post-
assessments to do with experience sampling; see Geschwind
et al20 for more information). Participants in the control
condition were offered the opportunity to take part in MBCTafter
the post-assessment. Participants in the MBCT condition
completed follow-up assessments 6 and 12 months after the end
of the training. Participant flow is displayed in Fig. 1.
Intervention (MBCT)
Content of the MBCT training sessions followed the protocol of
Segal et al.25 Training consisted of weekly meetings for 8 weeks
each lasting 2.5 h and these were run for groups of 10–15
participants (thus occasionally the groups were larger than the
usual 10–12 participants per group). Assessment periods for the
control participants were matched to those of the MBCT
participants. Sessions included guided meditation, experiential
exercises and discussions. In addition to the weekly group sessions,
participants received compact discs (CDs) with guided exercises and
were assigned daily homework exercises (30–60min daily). Training
sessions were delivered by experienced trainers in a centre specialised
in mindfulness training. All trainers were supervised by an
experienced healthcare professional who had trained with Teasdale
and Williams, the co-developers of MBCT.25
Measures
Hamilton Rating Scale for Depression (HRSD)
The 17-item HRSD was administered by trained research
assistants. The HRSD is a semi-structured interview designed to
assess depressive symptoms over the previous week.22 It is one
of the most frequently used rating scales in depression research,
and sensitivity, internal, interrater and retest reliability estimates
for the overall HRSD are good.26 Only the overall score was used
for the analyses, and interrater reliability for the total score was
high (intraclass correlation coefficient (ICC) = 0.97). To provide
information on interrater reliability, the interviewers had
independently rated eight videotaped HRSD interviews with
participants with varying levels of residual depressive symptoms.
Inventory of Depressive Symptoms (self-rating, IDS)
The IDS24 is a self-rated scale, which includes 30 items rated
zero to three. The scale is sensitive to change and has good
psychometric properties.24 Internal consistency in the current
sample was 0.85.
Statistical methods
We undertook an intention-to-treat analysis. Primary outcome
measures were residual depressive symptoms expressed as total
(interviewer-rated) HRSD score. Analyses were repeated using
(self-report) IDS total scores to verify whether results using
interviewer- and self-rated assessments corresponded with each
other. Linear regression analyses were used to examine the
interaction between treatment condition (control v. MBCT, coded
as zero and one, respectively) and number of previous depressive
episodes (one or two v. three or more, coded as zero and one,
respectively) in the model of (post) residual depressive symptoms,
corrected for baseline values. Stratified by number of prior
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Table 1 Baseline demographic and clinical characteristics by number of prior major depressive episodes
Measure
2 or fewer prior episodes
(n=71)
3 or more prior episodes
(n=59) t-test w2 P
Age, mean (s.d.) 42.8 (1.7) 45.2 (1.2) 1.43 0.15
Female gender, % 50 (70) 48 (81) 3.27 0.07
Full- or part-time work, % 53 (75) 32 (54) 9.63 50.002
Illness/unemployment benefits, % 13 (18) 15 (25) 1.45 0.23
Living with partner/own family, % 44 (62) 34 (58) 0.33 0.56
Comorbid anxiety disorder (present), % 25 (35) 29 (49) 3.4 0.06
Comorbid anxiety disorder (past), % 35 (50) 40 (68) 6.7 0.01
Current psycho-counselling/-therapy, % 7 (10) 10 (17) 2.1 0.15
Current use of antidepressants, % 21 (30) 25 (43) 3.65 0.06
(Occasional) use of benzodiazepines,a % 4 (6) 6 (10) 1.01 0.32
a. Yates’ w2 and Yates’ P-value reported because of low cell frequencies (55).
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depressive episodes, Cohen’s d and standardised effect sizes b
were calculated to express the effect of treatment on reduction
of residual symptoms. Residual depressive symptoms at 6- and
12-month follow-up (MBCT group only) were compared with
baseline and post-assessment scores, using paired t-tests. The
statistical package Stata 11 for Windows was used for all analyses.
Results
Participants
Recruitment started in January 2008 and ended in February 2009;
all post-intervention assessments were completed by August 2009,
when the predetermined number of participants was reached. At
baseline, there were no differences in sociodemographic and
clinical characteristics between the MBCT and the control
condition (see Geschwind et al20). Comparing participants with
three or more prior major depressive episodes (hereafter: ‘3+’)
and one or two prior episodes (hereafter: ‘2–’) revealed that
participants with 3+ prior episodes were less likely to work and
more likely to have had an anxiety disorder in the past, and were
marginally more likely to have a comorbid anxiety disorder, take
antidepressants, and be female (see Table 1). All analyses yielded
similar results when corrected for these variables.
Table 2 shows residual depressive symptoms by subgroup (3+
v. 2–) and treatment condition. Participant flow through the study
is displayed in Fig. 1. One participant completed only the HRSD
but not the IDS at post-measurement. No known harm or
unintended treatment effects were reported in either group. On
average, participants with 2– prior episodes randomised to MBCT
attended 7.3 sessions (s.d.= 1.6), and participants with 3+
attended 7.0 sessions (s.d.=1.4), with no significant difference
in attendance between the 2– and 3+ groups. Three MBCT
participants attended fewer than four sessions (two in the 2–
and one in the 3+ subgroups). There was no difference in daily
mindfulness practice between the 2– and 3+ MBCT subgroups
(t(61) = 0.94, P=0.35): participants in the 2– subgroup reported
practice for 25min (s.d. = 11) per day on average, and participants
in the 3+ subgroup reported a daily average of 28min (s.d. = 10).
Mindfulness practice was based on self-report and calculated as
minutes spent on long exercises (limited to a maximum of
45min, to prevent days of excessive practice skewing the average
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(n=198)
Assessed for eligibility
(n=144)
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(n=130)
Post
Analysis
6-month
follow-up
12-month
follow-up
Excluded (n=54)
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. Logistically not possible (n=7)
. Unlikely to meet inclusion criteria
after preliminary screening (n=22)
Excluded (n=14)
. Not meeting inclusion criteria (n=2)
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. Dropped out during experience sampling
baseline assessment (n=4)
Allocated to control (n=66)
Completed post intervention (n=66)
Analysed (n=66)
. Excluded from analysis (n=0)
Allocated to MBCT (n=64)
Completed post intervention (n=64)
. Discontinued intervention
(‘MBCT doesn’t suit me’) (n=3)
Analysed (n=64)
. Excluded from analysis (n=0)
Completed follow-up (n=58)
. Lost contact (n=6)
Completed follow-up (n=57)
. Lost contact (n=7)
6
6
6
6
6
6
6
7
7
6
6
6
Fig. 1 Participant flow diagram.
MBCT, mindfulness-based cognitive therapy; Control, waiting list control condition. Post-assessments took place after 8-weeks of MBCT or equivalent waiting time.
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score), plus minutes spent on short exercises. Overall, daily
mindfulness practice was positively and significantly associated
with improvements in residual depressive symptoms,
t(61) = 2.09, P= 0.04.
Effects of treatment condition
on residual depressive symptoms
Table 2 shows pre- and post-intervention means of residual
depressive symptoms by treatment condition and number of
episodes. The interaction between treatment condition (MBCT
v. control) and number of episodes (27 v. 3+) on reduction of
residual depressive symptoms was neither large nor significant
(HRSD: b= 0.45, 95% CI 70.18 to 1.07, t(125) = 1.41, P=0.16);
IDS-SR: b=0.33, 95% CI 70.22 to 0.89, t(124)= 3.27, P=0.24),
indicating that the effect of MBCT does not depend on the
number of depressive episodes. This was true for both the HRSD
and the IDS scores. Removing the non-significant interaction term
revealed a main effect of treatment condition (HRSD: b=70.56,
95% CI70.87 to70.25, t(126)= 3.56, P50.001); IDS: b=70.44,
95% CI 70.71 to 70.18, t(125) = 3.27, P50.001) but not of
number of episodes (HRSD: b= 0.20, 95% CI 70.11 to 0.51,
t(126) = 1.27, P= 0.21); IDS: b= 0.12, 95% CI 70.15 to 0.39,
t(125) = 0.87, P=0.39). Also when number of episodes was used
as a continuous variable (log-transformed to prevent problems
with skewness), there was no evidence for interaction with
treatment condition (HRSD: b=0.09, 95% CI 70.22 to 0.41,
t(114) = 0.58, P= 0.57; IDS: b= 0.17, 95% CI 70.11 to 0.45,
t(114) = 1.17, P= 0.24). Thus, MBCT was associated with a
significantly stronger reduction of residual depressive symptoms
across the whole sample. Treatment effect sizes within the two
subgroups are shown in Table 3.
Additional analyses on residual symptoms at 6- and 12-month
follow-up (available for MBCT group only) show that residual
depressive symptoms, compared with baseline, were still
significantly lower at both follow-up points (HRSD: t(57)6 months
=73.45, P= 0.001; t(56)12 months =75.15, P50.001). Moreover,
residual symptoms at follow-up did not differ from residual
symptoms at post-treatment (HRSD: t(57)6 months = 0.84,
P= 0.40; t(56)12 months =70.54, P= 0.59; comparable results from
IDS data). Figure 2 shows changes in residual depressive
symptoms by treatment condition and number of episodes.
Discussion
Across the whole sample, MBCT was associated with significant
post-treatment reductions of residual depressive symptoms
(approximately 30–35% reduction) in currently non-depressed
participants with residual symptoms of depression, compared
with a waiting list control condition (approximately 10%
reduction). Importantly, this RCT found no evidence for a
stronger effect of MBCT on residual depressive symptoms in
participants with three or more prior episodes compared with
participants with only one or two prior episodes. This finding
has implications for clinical practice because individuals with only
one or two prior episodes, given results of two earlier studies,
now typically are excluded from trials investigating the effects of
MBCT on residual depressive symptoms. Notably, these two
earlier studies examined patients without residual symptoms,
and used a different outcome measure (relapse/recurrence).13,14
Consequently, it may be argued that individuals with persistent
and harmful residual depressive symptoms originating from a first
or second episode should not be denied access to treatment that
can improve their quality of life and possibly decrease their risk
of relapse/recurrence. The finding that MBCT did not selectively
reduce residual depressive symptoms in individuals with three
or more prior episodes of depression cannot be attributed to
too low power, given that reductions in residual symptoms in
the MBCT v. the waiting list control group, if anything, were
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Table 2 Means (s.d.) of residual depressive symptomsa
Mean (s.d.)
Waiting list control condition Mindfulness-based cognitive therapy
Measure pre post pre post 6 months 12 months
1 or 2 prior episodes
Hamilton Rating Scale for Depression 10.5 (3.7) 9.8 (4.1) 9.6 (3.2) 5.9 (4.2) 6.5 (4.8) 5.3 (3.6)
Inventory of Depressive Symptoms 23.8 (8.8) 20.3 (9.9) 19.3 (9.4) 11.4 (8.9) 14.4 (10.8) 11.7 (8.1)
3 or more prior episodes
Hamilton Rating Scale for Depression 9.9 (3.4) 9.5 (4.0) 11.1 (4.1) 8.6 (5.1) 9.1 (6.8) 8.9 (5.0)
Inventory of Depressive Symptoms 20.5 (8.2) 17.9 (9.1) 26.0 (11.1) 18.6 (11.5) 19.2 (13.5) 20.0 (11.9)
Means (s.d.) of residual depressive symptoms by treatment condition, measurement occasion, and number of prior episodes of major depression. Baseline Inventory of Depressive
Symptoms (but not Hamilton Rating Scale for Depression) scores differed significantly between subgroup treatment conditions at baseline. Follow-up data are not available for
participants in the control condition, because they were offered the opportunity to take part in MBCT after post-measurement.
Table 3 Effect sizes of treatment (mindfulness-based cognitive therapy v. control), stratified by number of prior episodesa
Measure b (95% CI) t-test d.f. Cohen’s d
1 or 2 prior episodes
Hamilton Rating Scale for Depression 70.74 (71.13 to 70.35) 3.49*** 68 0.9
Inventory of Depressive Symptoms 70.60 (70.96 to 70.23) 3.29** 68 0.5
3 or more prior episodes
Hamilton Rating Scale for Depression 70.29 (70.80 to 0.22) 1.13 56b 0.5
Inventory of Depressive Symptoms 70.26 (70.71 to 0.18) 1.19 55 0.6
Control, waiting list control condition.
a. Effects are in favour of mindfulness-based cognitive therapy relative to control condition.
b. One participant completed only the Hamilton Rating Scale for Depression but not the Inventory of Depressive Symptoms at post-measurement.
**P50.01, ***P50.001.
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non-significantly larger in the group with one or two prior
episodes than the group with three or more.
Results suggest that general vulnerability to depression may
form an indication for MBCT (rather than a restriction based
on the number of recurrent episodes). Vulnerability may be
defined as recurrent depression (for example, Ma & Teasdale,13
Teasdale et al14), or as residual symptoms, similar to the present
study. Residual symptoms have a sizeable impact on quality of life
and represent a major risk factor for depressive relapse or
recurrence.27,28 Results of a recent trial,17 in which Segal et al
investigated the role of residual symptoms during remission with
regard to the efficacy of MBCT for relapse prevention, support the
idea that residual symptoms may co-determine efficacy of MBCT.
Mindfulness-based cognitive therapy was superior to placebo
(74% decrease in risk for relapse) and as effective as continuation
with active antidepressants only among participants who
experienced residual depressive symptoms during remission
(‘unstable remitters’). Among participants who did not experience
residual symptoms during remission (‘stable remitters’), there
was no difference between continuation with MBCT, active
antidepressants or placebo.
Clinical implications
Clinical implications following from this trial are that MBCT
treatment for residual symptoms should not be restricted to
individuals with three or more prior depressive episodes, although
replication is warranted. At the very least, this practice needs
urgent re-examination. Reduction of residual symptoms can be
expected to translate to improved quality of life as well as reduced
risk for relapse,9,28 although these variables were not measured in
the current study.
Strengths and limitations
Strengths of the current study include the systematic evaluation of
MBCT for subgroups of patients with one or two v. three or more
prior depressive episodes, as well as the large sample size of 71
participants with only one or two prior episodes of major
depression (compared with 32 and 18 in the original relapse
prevention studies13,14). Also, inclusion criteria were intentionally
kept broad to enhance generalisability with respect to the general
population of patients with depression. Finally, all randomised
participants were assessed on the main outcome measure at
baseline and post-intervention (without attrition), and adherence
to treatment was high, with only 3 of 64 MBCT participants
attending fewer than four out of eight sessions.
Some limitations also apply. First, comparison between the
MBCT and waiting list control condition was only possible
immediately post-treatment, because waiting list control
participants were given the opportunity to attend MBCT after
the post-measurements. However, 6- and 12-month follow-up
data for the MBCT group suggest that improvements in residual
depressive symptoms remain stable. Second, the broad inclusion
criteria led to a large amount of heterogeneity in current and
previous treatments, complicating fine-grained comparison of
treatment between groups. On the other hand, this was an RCT,
and participants were randomised within strata of one or two v.
three or more prior depressive episodes (thus in theory ensuring
an equal – or nearly equal – distribution of measured and
unmeasured confounders across subgroups). Although there were
no differences in sociodemographic and clinical variables between
the MBCT and waiting list control conditions, participants with
three or more prior depressive episodes seemed more pervasively
affected by the depressive disorder, compared with participants
with only one or two prior episodes (less likely to work, higher
comorbidity). Nevertheless, experiencing more pervasive
consequences as the number of depressive episodes increases is
entirely in line with clinical reality, and attempts to cancel out
such real-life differences statistically are not recommended.29
Third, the open-label, non-masked nature of the current trial
may have led to biased findings. However, analyses based on
interview v. self-report measures of residual depressive symptoms
yielded similar results, and therapists were masked to participants’
history of prior major depressive episodes. Fourth, limitations
include the absence of MBCT competence and adherence
measures, as well as the limited range of outcome measures.
Moreover, this RCT took place in a specialist setting and the
sample was partially recruited by posters in public spaces, raising
the possibility of self-selection biases. Replication in a more
traditional clinical setting, using additional outcome measures,
such as relapse/recurrence and quality of life, would be desirable.
Future studies may also include an active control group as well as
measures of self-help (using books or the internet).
In summary, the main benefit of the current study is that it
suggests that MBCT is also efficacious in individuals with only
one or two prior episodes of major depression given current
residual depressive symptoms. We hope that these findings, at
the very least, will lead to a renewed interest as to whether or
not MBCT is also indicated for individuals with fewer than three
previous episodes of major depression.
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